跳至主要内容
临床试验/EUCTR2015-003880-13-BG
EUCTR2015-003880-13-BG进行中(未招募)1 期

A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects with Schizophrenia

Alkermes Inc0 个研究点目标入组 277 人开始时间: 2016年4月1日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Alkermes Inc
入组人数
277

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subject has completed the 4-week treatment period (all visits up to and including end of treatment visit) in the antecedent study ALK3831-A305 within 7 days
  • Agrees to use an acceptable method of contraception for the duration of the study
  • Additional criteria may apply
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 370
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 20

排除标准

  • Subject is currently taking medications that are contraindicated with olanzapine use
  • Subject has a positive test for drugs of abuse at study entry
  • Subject is pregnant, planning to become pregnant, or breastfeeding during the study
  • Additional criteria may apply

研究者

发起方
Alkermes Inc

相似试验